Novan Files Paperwork for $60 Million IPO to Develop Skin Drugs

Published: Aug 26, 2016

Novan, a company researching ways to harness nitric oxide for drugmaking, has filed for an initial public offering to fund clinical work on treatments for an array of skin conditions.

Durham, NC-based Novan set a preliminary target of $60 million for the IPO, a figure that may change as the company works through how many shares it will sell and at what price.

Back to news